Back to Search Start Over

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.

Authors :
Nouailles G
Adler JM
Pennitz P
Peidli S
Teixeira Alves LG
Baumgardt M
Bushe J
Voss A
Langenhagen A
Langner C
Martin Vidal R
Pott F
Kazmierski J
Ebenig A
Lange MV
Mühlebach MD
Goekeri C
Simmons S
Xing N
Abdelgawad A
Herwig S
Cichon G
Niemeyer D
Drosten C
Goffinet C
Landthaler M
Blüthgen N
Wu H
Witzenrath M
Gruber AD
Praktiknjo SD
Osterrieder N
Wyler E
Kunec D
Trimpert J
Source :
Nature microbiology [Nat Microbiol] 2023 May; Vol. 8 (5), pp. 860-874. Date of Electronic Publication: 2023 Apr 03.
Publication Year :
2023

Abstract

Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
2058-5276
Volume :
8
Issue :
5
Database :
MEDLINE
Journal :
Nature microbiology
Publication Type :
Academic Journal
Accession number :
37012419
Full Text :
https://doi.org/10.1038/s41564-023-01352-8